Not exact matches
«Today's approval marks another first in the field of
gene therapy — both in how the
therapy works and in expanding the use of
gene therapy beyond the treatment of cancer to the treatment of vision loss — and this milestone reinforces the
potential of this breakthrough
approach in treating a wide - range of challenging diseases,» FDA Commissioner Scott Gottlieb said in a statement.
Despite this new direction for identifying targets for pharmaceutical interventions against RP, the researchers underscore that
gene therapy still has great
potential and possible benefits, and they are actively pursuing efforts with this
approach for several forms of RP.
«Today's approval marks another first in the field of
gene therapy — both in how the
therapy works and in expanding the use of
gene therapy beyond the treatment of cancer to the treatment of vision loss — and this milestone reinforces the
potential of this breakthrough
approach in treating a wide - range of challenging diseases,» FDA Commissioner Scott Gottlieb said in a statement.
Gene therapy has the
potential to provide reconstructive surgeons with a new
approach to solving one of their most difficult problems: the lack of adequate tissues to correct deformities of a specific area or structure.
«RNAi
therapies are a unique
approach to cancer treatment as they have the
potential to «turn off» the
genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.»
Activators of histone acetyltransferases (HAT) provide an alternative
approach for the selective activation of
gene expression, however little is known about the
potential of HAT activators as drug
therapies for PD.